BioNTech is a German biotechnology company founded in 2008, known for its development of innovative therapies and drugs using messenger RNA (mRNA) technology. The company gained global prominence for its collaboration with Pfizer in creating one of the first COVID-19 vaccines authorized for emergency use. BioNTech focuses on various areas including cancer immunotherapy, infectious diseases, and other serious ailments, aiming to harness the body’s immune system to fight diseases. Its mRNA technology platform has potential applications beyond vaccines, including personalized medicine and targeted treatments.
BioNTech is transitioning from COVID-19 vaccine success to developing pioneering cancer therapies using mRNA technology. The company faces financial challenges, reporting a €700 million net loss in 2024, yet has…